Cantor Fitzgerald’s Denali Therapeutics DNLI Stock Holding History

Cantor Fitzgerald’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-45,000	Closed	-$653K	–	259
2025 Q3	$653K	Buy	+45,000	New	+$647K	0.01%	268

Other funds holding DNLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cantor Fitzgerald's DNLI Position: Q4 2025 in Review

Cantor Fitzgerald sold out of Denali Therapeutics (DNLI) in Q4 2025, closing a stake of 45,000 shares — an estimated $653K sold.

Cantor Fitzgerald first reported a position in DNLI in Q3 2025 and held it in 1 quarter. The position peaked at $653K in Q3 2025. 250 funds tracked by Wall St. Rank hold DNLI as of Q4 2025.

Cantor Fitzgerald reported no remaining Denali Therapeutics position as of Q4 2025 after selling out during the quarter.
Cantor Fitzgerald sold 45,000 Denali Therapeutics shares in Q4 2025, an estimated $653K.
Cantor Fitzgerald first reported a position in Denali Therapeutics in Q3 2025 and held it in 1 quarter.
Cantor Fitzgerald's Denali Therapeutics position peaked at $653K in Q3 2025.
250 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2025.

Based on Cantor Fitzgerald's 13F filing for Q4 2025, filed 17 Feb 2026.